A student publication from 1969 made the same case for cannabis rescheduling that the DEA presented in federal proceedings this year, arguing that calls for more research were a stalling tactic that would never end.
The Marijuana Review, published from a Buffalo dorm room in January 1969, included poet Allen Ginsberg among its advisers and argued that existing scientific evidence on cannabis was already sufficient. The magazine went further, naming the individuals and institutions it predicted would spend decades demanding additional studies while blocking policy reform.
Fifty-seven years later, the DEA echoed that argument in recent federal rescheduling proceedings, contending that the scientific record on cannabis safety and medical utility is adequate despite ongoing objections that more research is needed.
The 1969 Prediction
The student editors wrote that opponents would perpetually claim insufficient evidence existed to support cannabis policy changes, regardless of how much research accumulated. They identified specific government officials and medical establishment figures who they believed would use the "more research needed" objection as a mechanism to prevent reform indefinitely.
That prediction proved accurate. For more than five decades, federal agencies and drug policy opponents have repeatedly cited the need for additional studies as justification for maintaining cannabis prohibition, even as the body of research on the plant grew substantially.
The magazine represented an early voice in what would become a multi-generational debate over cannabis policy. Its publication predated the Controlled Substances Act of 1970, which placed cannabis in Schedule I and created the regulatory framework that has governed federal drug policy since.
The DEA's Current Position
In recent federal proceedings related to rescheduling cannabis from Schedule I to Schedule III, DEA officials made arguments that mirror the 1969 magazine's analysis. The agency stated that existing research provides sufficient evidence to support rescheduling, pushing back against claims that more studies are required before any policy changes can occur.
The parallel arguments, separated by nearly six decades, highlight how little the fundamental terms of the cannabis policy debate have shifted at the federal level. The same objections raised in 1969 continue to surface in 2025, despite exponential growth in cannabis research, state-level legalization programs, and changes in public opinion.
Research studies on cannabis have increased dramatically since 1969, with thousands of peer-reviewed papers examining its medical applications, safety profile, and potential harms. Yet federal rescheduling efforts have faced consistent resistance from those arguing the evidence remains incomplete.
What Happens Next
The DEA's rescheduling process remains ongoing, with the agency reviewing public comments and scientific evidence as it considers moving cannabis to Schedule III. That change would acknowledge medical utility while maintaining federal control over the substance.
Critics of the rescheduling proposal argue it does not go far enough, advocating instead for full descheduling that would remove cannabis from the Controlled Substances Act entirely. Supporters counter that Schedule III represents meaningful progress after decades of federal inaction.
The Marijuana Review's 1969 prediction that research demands would serve as an indefinite barrier to reform has largely been validated by subsequent history. Whether that pattern finally breaks with current rescheduling efforts remains uncertain.
This article is based on original reporting by hightimes.com.
